scholarly journals Stroke Outcomes in Malawi, a Country with High Prevalence of HIV: A Prospective Follow-Up Study

PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e33765 ◽  
Author(s):  
Terttu Heikinheimo ◽  
Daniel Chimbayo ◽  
Johnstone J. Kumwenda ◽  
Sam Kampondeni ◽  
Theresa J. Allain
2003 ◽  
Vol 182 (4) ◽  
pp. 319-323 ◽  
Author(s):  
K. L. L. Movig ◽  
R. Baumgarten ◽  
H. G. M. Leufkens ◽  
J. H. M. Van Laarhoven ◽  
A. C. G. Egberts

BackgroundPolyuria is common in patients with bipolar disorder treated with lithium. However, the risk factors for polyuria in these patients have not been established.AimsTo estimate the prevalence of polyuria associated with the use of lithium and to identify additional risk factors.MethodA 4-month prospective follow-up study in an out-patient lithium clinic. The 75 participants were asked to provide 24-h urine samples; polyuria was defined as a urine volume greater than 3 litres per 24 h. Risk factors examined included demographic variables, medications and medical comorbidities.ResultsThe prevalence of polyuria among lithium users was 37%. Concomitant use of serotonergic antidepressants was strongly associated with polyuria (odds ratio 4.25, 95% CI 1.15–15.68) compared with patients not using these agents.ConclusionsOur data confirm the high prevalence of lithium-induced polyuria. Physicians should be aware that concurrent use of serotonergic antidepressants and lithium significantly enhances the risk of its occurrence. Although limited polyuria is not harmful, it may be troublesome for the patient. In many cases cessation of lithium therapy is not an option because of difficulty in controlling the manic or depressive symptoms.


2020 ◽  
Vol 11 ◽  
Author(s):  
Li Liu ◽  
Ping Yin ◽  
Chong Lu ◽  
Jingxin Li ◽  
Zhaoxia Zang ◽  
...  

2020 ◽  
Author(s):  
Dan Bhwana ◽  
Bruno P Mmbando ◽  
Alfred Dusabimana ◽  
Athanas Mhina ◽  
Daniel P Challe ◽  
...  

Abstract Background: Despite 20 years of ivermectin mass distribution in the Mahenge area, Tanzania, the prevalence of onchocerciasis and epilepsy has remained high in rural villages. We investigated the efficacy of ivermectin in reducing Onchocerca volvulus microfilariae and predictors for parasitic load following ivermectin treatment in persons with and without epilepsy in two rural villages.Methods: Between April and September 2019, 50 persons with epilepsy (PWE) and 160 randomly selected persons without epilepsy (PWOE) from Msogezi and Mdindo villages participated in a follow-up study. Skin snips were obtained pre- (baseline) and three months post-ivermectin treatment.Results: The overall prevalence of O. volvulus positive skin snips at baseline was 49% (103/210), with no significant difference between PWE (58.0%) and PWOE (46.3%); p=0.197. The overall median microfilarial density was significantly higher at baseline (0.0 mf/mg, IQR: 0.0-1.7) than three month post-ivermectin treatment (0.0 mf/mg, IQR: 0.0-0.0), p<0.001. Three months after ivermectin, the microfilarial density had decreased by ≥80% in 54 (81.8%, 95%CI: 72.3-91.4) of the 66 individuals with positive skin snips at baseline. High microfilarial density at baseline was the only significant predictor associated with higher microfilarial density in the post-ivermectin skin snips. Conclusion: Our study reports a satisfactory decrease in microfilarial density following ivermectin treatment in most individuals. This suggests that optimizing ivermectin coverage will address the ongoing onchocerciasis transmission in Mahenge.


Sign in / Sign up

Export Citation Format

Share Document